BioHeart, which focuses on using cells derived from a patient's body for treatment of heart damage, filed terms Thursday with the SEC for its upcoming iPO. The company plans to offer 3.6 million shares at a price range of $14 to $16 per share. BMO Capital Markets is the lead manager on the deal.
